Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00027183|
Recruitment Status : Completed
First Posted : November 28, 2001
Last Update Posted : May 25, 2022
Some bacteria that cause disease can produce toxic substances that may worsen the disease. Pseudomonas aeruginosa is a bacteria that can produce a variety of toxins and is of special interest for patients with cystic fibrosis and repeated long term lung infections.
The goal of this study is to determine whether specific toxins produced by Pseudomonas aeruginosa may be important in the disease process of chronic lung infections of patients with cystic fibrosis.
This study will attempt to measure bacterial production of toxins in blood and sputum and immune system response to toxins in the blood.
|Condition or disease|
|Pseudomonas Infection Cystic Fibrosis|
|Study Type :||Observational|
|Actual Enrollment :||134 participants|
|Official Title:||Role of Exotoxins in the Pathogenesis of Pseudomonas Aeruginosa|
|Actual Study Start Date :||March 17, 1998|
Cystic Fibrosis subjects
- Serum will be analyzed for the presence of an immune response, focusing on antibodies against the virulence determinants, whilesputum will be analyzed for the immunological and genetic presence of the virulence determinants. [ Time Frame: End of Study ]serum will be analyzed for the presence of an immune response, focusing on antibodies against the virulence determinants, whilesputum will be analyzed for the immunological and genetic presence of the virulence determinants.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00027183
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Joel Moss, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|